R. Lemay

发表

Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry

C. Eng, R. Hopkin, W. Wilcox, 2008, Pediatric Research.

Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry

Manesh R. Patel, Philip J. Lee, S. Waldek, 2009, Genetics in Medicine.

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease

S. Packman, J. Charrow, R. Desnick, 2015, Journal of Medical Genetics.

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation

J. Oliveira, C. Wanner, D. Beitner-Johnson, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.

P. Kaplan, P. Kishnani, G. Pastores, 2009, Molecular genetics and metabolism.

Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup

J. Oliveira, C. Wanner, D. Warnock, 2020, Journal of Medical Genetics.

Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.

F. Weidemann, R. Hopkin, W. Wilcox, 2018, JIMD reports.

Fabry disease in latin america: data from the fabry registry.

J. Politei, H. Amartino, S. S. Ordoñez, 2013, JIMD reports.

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

J. Oliveira, C. Wanner, C. Eng, 2008, Molecular genetics and metabolism.

Improvement of Fabry disease related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta

F. Weidemann, R. Hopkin, W. Wilcox, 2016 .

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

J. Oliveira, C. Wanner, D. Warnock, 2010, Clinical journal of the American Society of Nephrology : CJASN.

10. Life expectancy and cause of death in Fabry disease: Findings from the Fabry Registry

S. Waldek, M. Banikazemi, R. Lemay, 2010 .

Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.

J. Charrow, D. Warnock, R. Hopkin, 2016, Molecular genetics and metabolism.

Female Fabry disease: significant improvement of Fabry disease-related gastrointestinal symptoms in a large cohort of female patients treated with agalsidase beta: data from the Fabry Registry

F. Weidemann, R. Hopkin, W. Wilcox, 2014 .

P24—Prognostic Indicators of Renal Disease Progression: Natural History Data From the Fabry Registry

J. Oliveira, C. Wanner, D. Warnock, 2012 .

Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.

J. Charrow, D. Warnock, R. Hopkin, 2016, Molecular genetics and metabolism.

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

J. Oliveira, C. Wanner, D. Warnock, 2010, Clinical journal of the American Society of Nephrology : CJASN.